Trofinetide - Neuren Pharmaceuticals

Drug Profile

Trofinetide - Neuren Pharmaceuticals

Alternative Names: G-2Me-PE; Glycyl-2-methyl-L-prolyl-L-glutamic acid; Glycyl-L-2-methylprolyl-L-glutamic acid; NNZ-2566

Latest Information Update: 14 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neuren Pharmaceuticals
  • Developer Neuren Pharmaceuticals; Rettsyndrome.org; Walter Reed Army Institute of Research
  • Class Glutamates; Neuropeptides; Neuroprotectants; Oligopeptides; Pyrrolidines; Small molecules
  • Mechanism of Action Cytokine inhibitors; Glial cell modulators; Neuropeptide receptor modulators; Synaptic transmission modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome; Rett syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Brain injuries; Fragile X syndrome; Rett syndrome
  • Preclinical Multiple sclerosis
  • No development reported Autistic disorder

Most Recent Events

  • 06 Aug 2018 Trofinetide licensed to ACADIA Pharmaceuticals in North America
  • 06 Aug 2018 ACADIA Pharmaceuticals plans a phase III trial for Rett syndrome in North America in second half of 2019
  • 21 May 2018 Neuren Pharmaceuticals and undisclosed pharmaceutical company agree to co-promote and co-develop trofinetide for brain injury, Rett syndrome, Fragile X syndrome and neurodegenerative disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top